fashion -WSS

fashion

author：focus 2025-08-12 11:30:08 - browse：12

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Stop Congress from blocking public access to science

focus

WSS

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The United States is paying nearly triple for new Covid vaccines

Setback for rare diseases as Taysha Gene Therapies pulls back

People can get long Covid without testing positive for virus: Study

The stability of $0 premiums in Medicare Advantage

CDC says it’s too soon to assess risk posed by Covid subvariant

entertainment

fashion

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The stability of $0 premiums in Medicare Advantage

Supreme Court strikes down use of affirmative action

National associations that represent hospice owe an apology

Heart attack and stroke risk calculators need revising

Wegovy improves function in certain heart failure patients

Drug repurposing or repositioning? The language matters

CDC says it’s too soon to assess risk posed by Covid subvariant

Continuity nursing helped my family in our darkest PICU moments

European officials brace for rough respiratory virus season

explore

Setback for rare diseases as Taysha Gene Therapies pulls back

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Study: Spinal cord stimulation helps patients with paralysis walk again

FDA greenlights medical device to combat bladder issues

Nobel honors Karikó and Weissman's enduring partnership

WHO recommends second malaria vaccine

focus

focus

focus

focus